Reliable online water quality monitoring as basis for fault tolerant control

Authors: Edthofer, F., van den Broeke, J., Ettl, J., Lettl, W., Weingartner, A.

Source: 2010 Conference on Control and Fault-Tolerant Systems (SysTol) Control and Fault-Tolerant Systems (SysTol), 2010 Conference on. :57-62 Oct, 2010

Relation: 2010 Conference on Control and Fault-Tolerant Systems (SysTol)

Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study

Authors: Jimenez, M.M., Johnston, S., Boyle, F., Steger, G.G., Neven, P., Jiang, Z., Campone, M., Huober, J., Shimizu, C., Cicin, I., Wardley, A., Tolaney, S.M., Abuin, G.G., Zarba, J., Lim, E., Sant, P., Liao, N., Christiansen, B., Eigeliene, N., Martin-Babau, J., Ettl, J., Mavroudis, D., Chiu, J., Boer, K., Nagarkar, R., Paluch-Shimon, S., Moscetti, L., Sagara, Y., Kim, S.-B., Maciel, M.M., Tjan-Heijnen, V., Broom, R., Lacko, A., Schenker, M., Volkov, N., Sim Yap, Y., Coccia-Portugal, M., Ángel García Sáenz, J., Andersson, A., Chao, T.-Y., Gokmen, E., Harputluoglu, H., Berzoy, O., Patt, D., McArthur, H., Chew, H., Chalasani, P., Kaufman, P., Tedesco, K., Graff, S.L., Harbeck, N., Rastogi, P., Martin, M., Shao, Z.M., Fasching, P.A., Huang, C.S., Jaliffe, G.G., Tryakin, A., Goetz, M.P., Rugo, H.S., Senkus, E., Testa, L., Andersson, M., Tamura, K., Del Mastro, L., Kreipe, H., Hegg, R., Sohn, J., Guarneri, V., Cortés, J., Hamilton, E., André, V., Wei, R., Barriga, S., Sherwood, S., Forrester, T., Munoz, M., Shahir, A., San Antonio, B., Nabinger, S.C., Toi, M., Johnston, S.R.D., O’Shaughnessy, J.

Source: In Annals of Oncology December 2021 32(12):1571-1581

Final results from the PERUSE study of first-line pertuzumab plus trastuzumab plus a taxane for HER2-positive locally recurrent or metastatic breast cancer, with a multivariable approach to guide prognostication

Authors: Bachelot, T., Bouzid, K., Campone, M., Desmoulins, I., Coudert, B., Bondarenko, I., Nowecki, Z., Glogowska, I., Ciruelos Gil, E., Errihani, H., Dalenc, F., Ricci, F., Dieras, V., Kaufman, B., Paluch-Shimon, S., Wardley, A., Schneeweiss, A., Ferreira, A., Mano, M., Kalofonos, H., Andreetta, C., Puglisi, F., Montemurro, F., Barrett, S., Zhang, Q., Mavroudis, D., Matus, J., Villarreal Garza, C., Beato, C., Ismael, G., Hu, X., Abdel Azeem, H., Gaafar, R., Perrin, C., Kerbrat, P., Ettl, J., Paepke, S., Hitre, E., Lang, I., Trudeau, M., Verma, S., Li, H., Hoffmann, O., Aktas, B., Cariello, A., Cruciani, G., Tienghi, A., Tondini, C., Al-Twegieri, T., Loman, N., Laing, R., Miles, D., Brain, E., Fasching, P., Lux, M., Frassoldati, A., Aziz, Z., Salas, J., Streb, J., Krzemieniecki, K., Wronski, A., Garcia Garcia, J., Menjon Beltran, S., Cicin, I., Schmid, P., Gallagher, C., Turner, N., Tong, Z., Boer, K., Juhász, B., Horvath, Z., Bianchini, G., Gianni, L., Curigliano, G., Juarez Ramiro, A., Susnjar, S., Matos, E., Sevillano, E., Garcia Estevez, L., Gokmen, E., Uslu, R., Wildiers, H., Schutz, F., Cruz, M., Bourgeois, H., von Schumann, R., Stemmer, S., Dominguez, A., Morales-Vásques, F., Wojtukiewicz, M., Trifunovic, J., Echarri Gonzalez, M.J., Illarramendi Mañas, J., Martinez De Dueñas, E., Voitko, N., Hicks, J., Waters, S., Barrett-Lee, P., Wheatley, D., De Boer, R., Cocquyt, V., Jerusalem, G., Barrios, C., Panasci, L., Mattson, J., Tanner, M., Gozy, M., Vasilopoulos, G., Papandreou, C., Revesz, J., Battelli, N., Benedetti, G., Latini, L., Gridelli, C., Lazaro Leon, J., Alarcón Company, J., Arance Fernandez, A., Barnadas Molins, A., Calvo Plaza, I., Bratos, R., Gonzalez Martin, A., Izarzugaza Peron, Y., Klint, L., Kovalev, A., McCarthy, N., Yeo, B., Kee, D., Thomson, J., White, S., Greil, R., Wang, S., Artignan, X., Juhasz-Böess, I., Rody, A., Ngan, R., Dourleshter, F., Goldberg, H., Doni, L., Di Costanzo, F., Ferraù, F., Drobniene, M., Aleknavicius, E., Rashid, K., Costa, L., de la Cruz Merino, L., Garcia Saenz, J., López, R., Del Val Munoz, O., Ozyilkan, O., Azribi, F., Jaafar, H., Baird, R., Verrill, M., Beith, J., Petzer, A., Moreira de Andrade, J., Bernstein, V., Macpherson, N., Rayson, D., Saad Eldin, I., Achille, M., Augereau, P., Müller, V., Rasco, A., Evron, E., Katz, D., Berardi, R., Cascinu, S., De Censi, A., Gennari, A., El-Saghir, N., Ghosn, M., Oosterkamp, H.M., Van den Bosch, J., Kukulska, M., Kalinka, E., Alonso, J., Dalmau Portulas, E., Del Mar Gordon Santiago, M., Pelaez Fernandez, I., Aksoy, S., Altundag, K., Senol Coskun, H., Bozcuk, H., Shparyk, Y., Barraclough, L., Levitt, N., Panwar, U., Kelly, S., Rigg, A., Varughese, M., Castillo, C., Fein, L., Malik, L., Stuart-Harris, R., Singer, C., Stoeger, H., Samonigg, H., Feng, J., Cedeño, M., Ruohola, J., Berdah, J.-F., Goncalves, A., Orfeuvre, H., Grischke, E.-M., Simon, E., Wagner, S., Koumakis, G., Papazisis, K., Ben Baruch, N., Fried, G., Geffen, D., Karminsky, N., Peretz, T., Cavanna, L., Pedrazzioli, P., Grasso, D., Ruggeri, E., D’Auria, G., Moscetti, L., Juozaityte, E., Rodriguez Cid, J., Roerdink, H., Siddiqi, N., Passos Coelho, J., Arcediano Del Amo, A., Garcia Garre, E., García Gonzalez, M., Garcia-Palomo Perez, A., Herenandez Perez, C., Lopez Alvarez, P., Lopez De Ceballos, M.H., Martínez Jañez, N., Mele Olive, M., McAdam, K., Perren, T., Dunn, G., Humphreys, A., Taylor, W., Vera, R., Kaen, L., Andel, J., Steger, G., De Grève, J., Huizing, M., Hegg, R., Joy, A., Kuruvilla, P., Sehdev, S., Smiljanic, S., Kütner, R., Alexandre, J., Grosjean, J., Laplaige, P., Largillier, R., Maes, P., Martin, P., Pottier, V., Christensen, B., Khandan, F., Lück, H.-J., Zahm, D.-M., Fountzilas, G., Karavasilis, V., Safra, T., Inbar, M., Ryvo, L., Bonetti, A., Seles, E., Giacobino, A., Chavarri Guerra, Y., de Jongh, F., van der Velden, A., van Warmerdam, L., Vrijaldenhoven, S., Smorenburg, C.H., Cavero, M., Andres Conejero, R., Oltra Ferrando, A., Redondo Sanchez, A., Ribelles Entrena, N., Saura Grau, S., Viñas Vilaro, G., Bachmeier, K., Beresford, M., Butt, M., Joffe, J., Poole, C., Woodings, P., Chakraborti, P., Yordi, G., Woodward, N., Nobre, A., Luiz Amorim, G., Califaretti, N., Fox, S., Robidoux, A., Li, E., Li, N., Jiang, J., Soria, T., Padrik, P., Lahdenpera, O., Barletta, H., Dohollou, N., Genet, D., Prulhiere, K., Coeffic, D., Facchini, T., Vieillot, S., Catala, S., Teixeira, L., Hesse, T., Kühn, T., Ober, A., Repp, R., Schröder, W., Pectasides, D., Bodoky, G., Kahan, Z., Jiveliouk, I., Rosengarten, O., Rossi, V., Alabiso, O., Pérez Martínez, M., van de Wouw, A.J., Smok-Kalwat, J., Damasecno, M., Augusto, I., Sousa, G., Saadein, A., Abdelhafiez, N., Abulkhair, O., Antón Torres, A., Corbellas Aparicio, M., Llorente Domenech, R., Florián Jerico, J., Garcia Mata, J., Gil Raga, M., Galan Brotons, A., Llombart Cussac, A., Llorca Ferrandiz, C., Martinez Del Prado, P., Olier Garate, C., Rodriguez Sanchez, C., Sanchez Gomez, R., Santisteban Eslava, M., Soberino, J., Vidal Losada Garcia, M., Soto de Prado, D., Torrego Garcia, J., Vicente Rubio, E., Garcia, M., Murias Rosales, A., Granstam Björneklett, H., Narbe, U., Jafri, M., Rea, D., Newby, J., Jones, A., Westwell, S., Ring, A., Alonso, I., Rodríguez, R., Ciruelos, E., Peretz-Yablonski, T., Merot, J.-L., Trask, P., du Toit, Y., Pena-Murillo, C., Revelant, V., Klingbiel, D.

Source: In Annals of Oncology October 2021 32(10):1245-1255

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Authors: Litton, J.K., Hurvitz, S.A., Mina, L.A., Rugo, H.S., Lee, K.-H., Gonçalves, A., Diab, S., Woodward, N., Goodwin, A., Yerushalmi, R., Roché, H., Im, Y.-H., Eiermann, W., Quek, R.G.W., Usari, T., Lanzalone, S., Czibere, A., Blum, J.L., Martin, M., Ettl, J.

Source: In Annals of Oncology November 2020 31(11):1526-1535

Quality of life with talazoparib after platinum or multiple cytotoxic non-platinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations: patient-reported outcomes from the ABRAZO phase 2 trial

Authors: Hurvitz, S.A., Quek, R.G.W., Turner, N.C., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E., Mina, L.A., Balmaña, J., Fasching, P.A., Bhattacharyya, H., Hannah, A.L., Robson, M.E., Wardley, A.M.

Source: In European Journal of Cancer November 2018 104:160-168

Quality of life with talazoparib versus physician’s choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation: patient-reported outcomes from the EMBRACA phase III trial

Authors: Ettl, J. ^*, Quek, R.G.W., Lee, K.-H., Rugo, H.S., Hurvitz, S., Gonçalves, A., Fehrenbacher, L., Yerushalmi, R., Mina, L.A., Martin, M., Roché, H., Im, Y.-H., Markova, D., Bhattacharyya, H., Hannah, A.L., Eiermann, W., Blum, J.L., Litton, J.K.

Source: In Annals of Oncology September 2018 29(9):1939-1947

Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial

Authors: Rugo, H.S. ^*, Diéras, V., Gelmon, K.A., Finn, R.S., Slamon, D.J., Martin, M., Neven, P., Shparyk, Y., Mori, A., Lu, D.R., Bhattacharyya, H., Bartlett, C.H.u.a.n.g., Iyer, S., Johnston, S., Ettl, J., Harbeck, N.

Source: In Annals of Oncology April 2018 29(4):888-894

Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases

Authors: Turner, N.C. ^*, Finn, R.S., Martin, M., Im, S.-A., DeMichele, A., Ettl, J., Diéras, V., Moulder, S., Lipatov, O., Colleoni, M., Cristofanilli, M., Lu, D.R., Mori, A., Giorgetti, C., Iyer, S., Bartlett, C. Huang, Gelmon, K.A.

Source: In Annals of Oncology March 2018 29(3):669-680

Time trends (2006–2015) of quality indicators in EUSOMA-certified breast centres

Authors: Badbanchi, F., Catalano, G., Cretella, E., Daniaux, M., Emons, A., van Eygen, K., Ettl, J., Gatzemeier, W., Kern, P., Schneeweiss, A., Stoeblen, F., Van As, A., Wuerstlein, R., Zanini, V., van Dam, P.A., Tomatis, M., Marotti, L., Heil, J., Mansel, R.E., Rosselli del Turco, M., van Dam, P.J., Casella, D., Bassani, L.G., Danei, M., Denk, A., Egle, D., Emons, G., Friedrichs, K., Harbeck, N., Kiechle, M., Kimmig, R., Koehler, U., Kuemmel, S., Maass, N., Mayr, C., Prové, A., Rageth, C., Regolo, L., Lorenz-Salehi, F., Sarlos, D., Singer, C., Sohn, C., Staelens, G., Tinterri, C., Audisio, R., Ponti, A.

Source: In European Journal of Cancer November 2017 85:15-22

An autonomic station for measuring air pollutants in remote areas.

Authors: Balzer, W. (Wolfgang), Ettl, J., Reiniger, K.

Source: Atmospheric Environment (00046981); 1987, Vol. 21 Issue 1, p179-183, 5p

272P Outcomes of patients (pts) who had received prior platinum (PP) therapy in the phase III EMBRACA trial of talazoparib (TALA) vs physician’s choice of chemotherapy (PCT) in patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC)

Authors: Martin, M., Rugo, H.S., Hurvitz, S.A., Ettl, J., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.

Source: In Annals of Oncology September 2021 32 Supplement 5:S481-S481

273P Talazoparib (TALA) for patients with germline BRCA1/2 mutated (gBRCA1/2mut) advanced breast cancer (ABC): Characteristics of patients who experienced hematologic toxicity in the phase III EMBRACA trial

Authors: Hurvitz, S.A., Rugo, H.S., Ettl, J., Martin, M., Roche, H., Lee, K-H., Goodwin, A., Usari, T., Lanzalone, S., Guenzel, C.A., Blum, J., Litton, J.K.

Source: In Annals of Oncology September 2021 32 Supplement 5:S482-S482

203P Randomized study of single-agent metronomic versus weekly oral vinorelbine (VNR) as first-line chemotherapy in patients with HR+/HER2- advanced breast cancer

Authors: Cazzaniga, M.E., Martinez Jañez, N., Kukielka-Budny, B.D., Ulanska, M., Bourgeois, H., Muñoz Mateu, M., Morales Murillo, S., Bayo, J., Cortesi, L., Pinter, T., Palacova, M., Cherciu, N., Petru, E., Ettl, J., De Almeida, C., Raymond, R., Villanova, G.R., Thanh Minh, C. Ta, Rodrigues, A.C.F., Freyer, G.

Source: In Annals of Oncology September 2021 32 Supplement 5:S447-S447

Postneoadjuvante Therapiekonzepte beim Mammakarzinom. (German)

Alternate Title: Postneoadjuvant treatment concepts for breast cancer. (English)

Authors: Ettl, J., Stewart-da Coll, J.

Source: Best Practice Onkologie; Mar2021, Vol. 16 Issue 3, p90-94, 5p

Boundary Layer Transit Flight Experiment: Mission Overview, Launch Vehicle and Payload Subsystems.

Authors: Hörschgen-Eggers, M.¹, Kirchhartz, R. M.², Jung, W.³, Schoppmann, K.⁴, Ettl, J.⁵, Wittkamp, M.⁶

Source: Journal of Spacecraft & Rockets; Jan2021, Vol. 58 Issue 1, p26-37, 12p

357TiP SGNLVA-002: Single arm, open-label, phase Ib/II study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer

Authors: Cortés, J., Diab, S., Basho, R.K., Oliveira, M., Pluard, T., Alemany, C., Brown-Glaberman, U., Meisel, J., Boni, V., Sinha, R., Estevez, L. García, Ettl, J., Kuemmel, S., Sanchez, L.M. Manso, Moon, Y.W., Vazquez, R. Villanueva, Wuerstlein, R., Wang, Y., Wang, Z., Han, H.

Source: In Annals of Oncology September 2020 31 Supplement 4:S393-S393

PCN491 PATIENT REPORTED OUTCOMES (PRO) OF TALAZOPARIB (TALA) VERSUS PHYSICIAN'S CHOICE OF CHEMOTHERAPY (PCT) IN PATIENTS (PTS) WITH ADVANCED BREAST CANCER (ABC) AND A GERMLINE BRCA (GBRCA) MUTATION: A FOCUS ON EMBRACA PTS WITH/ WITHOUT PRIOR CHEMOTHERAPY (CT) SUBGROUPS

Authors: Quek, R.G.W., Bhattacharyya, H., Goncalves, A., Rugo, H.S., Hurvitz, S.A., Ettl, J.

Source: In Value in Health November 2019 22 Supplement 3:S532-S532

387TiP - Palbociclib rechallenge in hormone receptor (HR)[+]/HER2[-] advanced breast cancer (ABC). PALMIRA trial

Authors: Llombart Cussac, A., Medioni, J., Colleoni, M.A., Ettl, J., Schmid, P., Macpherson, I., Gligorov, J., Albanell, J., Bellet Ezquerra, M., Fernández, A., Ruiz Borrego, M., Gavilá-Gregori, J., Wheatley, D., Zamora, P., Martínez, E., Sampayo, M., Riva, F., Malfettone, A., Pérez-García, J.M., Cortés, J.

Source: In Annals of Oncology October 2019 30 Supplement 5:v141-v141

357P - Patient Reported Outcomes (PRO) in patients (pts) with HER2- advanced breast cancer (ABC) and a germline BRCA1/2 mutation (gBRCAm) receiving talazoparib (TALA) vs physician’s choice chemotherapy (PCT) in the EMBRACA trial: A focus on subgroups with/ without visceral disease

Authors: Ettl, J., Quek, R.G.W., Bhattacharyya, H., Rugo, H.S., Hurvitz, S.A., Gonçalves, A.

Source: In Annals of Oncology October 2019 30 Supplement 5:v129-v130

314P - Next-generation DNA sequencing (NGS) results for tumours from phase II ABRAZO study of talazoparib after platinum or cytotoxic non-platinum regimens in patients (pts) with advanced breast cancer (ABC) and germline BRCA1/2 (gBRCA) mutations

Authors: Turner, N.C., Laird, A.D., Telli, M.L., Rugo, H.S., Mailliez, A., Ettl, J., Grischke, E.-M., Mina, L.A., Balmaña, J., Fasching, P.A., Hurvitz, S.A., Albacker, L.A., Frampton, G.M., Chelliserry, J., Bycott, P., Conte, U., Wardley, A.M., Robson, M.E.

Source: In Annals of Oncology October 2019 30 Supplement 5:v108-v109